Overview

Cern Corporation, Inc. is a Southern California based Delaware “C” corporation formed to develop and commercialize an effective, non-drug (drug/photosensitizer optional) therapeutic treatment for fungal and bacterial vaginosis using low-level microbicidal light, administered as a small insertable device for use at home as needed. The device will be available in various form factors via a doctor’s prescription and will mitigate undesirable pathogen in the lower GYN tract with minimal commensal effect. The Cern Device™ addresses a significant unmet need for an effective science-based approach, not dependent on drugs/chemistries for efficacy to aid a population unable, or have a preference to, avoid conventional drug-based treatments which may not be effective or appropriate based on patient condition (e.g., maternity, immunocompromised, drug resistant, recurrent, multi-drug interactions). The device addresses a significant interest by women and clinicians to lessen intake of drugs/chemistries which is particularly important when associated with overuse of antifungals & antibiotics leading to development of drug resistant strains as well as the added benefit of helping to avoid complex drug interactions as well as to mitigate newly appearing fungal strains not which are also resistant to current standards of care. The device also aligns with telemedicine. Once the device is prescribed, the healthcare provider has ability to interface remotely with the patient to activate usage based on “normal” recurring symptoms after a “remote” consult. Additional user data and outcome feedback can be captured to facilitate data flow for epidemiology and education. The team includes experts from medical device industry, academia, and healthcare, all focused on bringing this new treatment to market.